

## Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

In this article (Clin Cancer Res 2016;22:1095–102), which was published in the March 1, 2016, issue of *Clinical Cancer Research* (1), the corresponding author informed us of a labeling error in Fig. 1D in the published article. This figure depicts the relationship between pMAPKAP-K2 percent inhibition from baseline and ralimetinib plasma concentration at matching time points. The figure legend and associated text refer to the data as being from "cycle 1 day 1." However, the current plot is actually pharmacokinetic/pharmacodynamic data from "cycle 1 day 14."

On page 1098, the legend for Fig. 1D should read as follows:

D, the relationship between pMAPKAP-K2 percent inhibition from baseline and ralimetinib plasma concentration at matching time points following the cycle 1 day 14. Error bars represent SD.

On page 1100, the paragraph under the "Pharmacodynamics" heading in the Results section should read as follows:

The primary pharmacodynamic biomarker in this study was p-MAPKAP-K2. Figure 1D illustrates the relationship between p-MAPKAP-K2 percent inhibition from baseline and ralimetinib plasma concentration at matching time points following the cycle 1 day 14 dose. In general, there was a reciprocal relationship between ralimetinib plasma concentration and pMAPKAPK-2 inhibition. At the dose of 300 mg in Part C and in Part D, the average pMAPKAPK-2 inhibition reached above 50% on day 1.

The conclusions put forth in this article remain unchanged. The authors regret this error.

### Reference

1. Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, et al. A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer. Clin Cancer Res 2016;22:1095–102.

Published online May 13, 2016.

doi: 10.1158/1078-0432.CCR-16-0645

©2016 American Association for Cancer Research.

# Clinical Cancer Research

## Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

*Clin Cancer Res* 2016;22:2596.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/22/10/2596>

**Cited articles** This article cites 1 articles, 1 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/22/10/2596.full#ref-list-1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/22/10/2596>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.